Scales to assess psychosis in Parkinson's disease: Critique and recommendations.
Identifieur interne : 002090 ( PubMed/Checkpoint ); précédent : 002089; suivant : 002091Scales to assess psychosis in Parkinson's disease: Critique and recommendations.
Auteurs : Hubert H. Fernandez [États-Unis] ; Dag Aarsland ; Gilles Fénelon ; Joseph H. Friedman ; Laura Marsh ; Alexander I. Tröster ; Werner Poewe [Autriche] ; Olivier Rascol ; Cristina Sampaio ; Glenn T. Stebbins ; Christopher G. GoetzSource :
- Movement disorders : official journal of the Movement Disorder Society [ 1531-8257 ] ; 2008.
English descriptors
- KwdEn :
- Brief Psychiatric Rating Scale, Delusions (diagnosis), Delusions (epidemiology), Delusions (etiology), Diagnostic and Statistical Manual of Mental Disorders, Hallucinations (diagnosis), Hallucinations (epidemiology), Hallucinations (etiology), Health Planning Guidelines, Humans, Parkinson Disease (epidemiology), Parkinson Disease (psychology), Prevalence, Psychometrics, Psychotic Disorders (diagnosis), Psychotic Disorders (epidemiology), Psychotic Disorders (etiology), Questionnaires, Severity of Illness Index.
- MESH :
- diagnosis : Delusions, Hallucinations, Psychotic Disorders.
- epidemiology : Delusions, Hallucinations, Parkinson Disease, Psychotic Disorders.
- etiology : Delusions, Hallucinations, Psychotic Disorders.
- psychology : Parkinson Disease.
- Brief Psychiatric Rating Scale, Diagnostic and Statistical Manual of Mental Disorders, Health Planning Guidelines, Humans, Prevalence, Psychometrics, Questionnaires, Severity of Illness Index.
Abstract
Psychotic symptoms are a frequent occurrence in Parkinson's disease (PD), affecting up to 50% of patients. The Movement Disorder Society established a Task Force on Rating Scales in PD, and this critique applies to published, peer-reviewed rating psychosis scales used in PD psychosis studies. Twelve psychosis scales/questionnaires were reviewed. None of the reviewed scales adequately captured the entire phenomenology of PD psychosis. While the Task Force has labeled some scales as "recommended" or "suggested" based on the fulfilling-defined criteria, none of the current scales contained all the basic content, mechanistic and psychometric properties needed to capture PD psychotic phenomena and to measure clinical response over time. Different scales may be better for some settings versus others. Since one scale may not be able to serve all needs, a scale used to measure clinical response and change over time [such as the Clinical Global Impression Scale (CGIS)] may need to be combined with another scale better at cataloging specific features [such as the Neuropsychiatric Inventory (NPI) or Schedule for Assessment of Positive Symptoms (SAPS)]. At the present time, for clinical trials on PD psychosis assessing new treatments, the following are recommended primary outcome scales: NPI (for the cognitively impaired PD population or when a caregiver is required), SAPS, Positive and Negative Syndrome Scale (PANSS), or Brief Psychiatric Rating Scale (BPRS) (for the cognitively intact PD population or when the patient is the sole informant). The CGIS is suggested as a secondary outcome scale to measure change and response to treatment over time.
DOI: 10.1002/mds.21875
PubMed: 18175343
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:18175343Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Scales to assess psychosis in Parkinson's disease: Critique and recommendations.</title><author><name sortKey="Fernandez, Hubert H" sort="Fernandez, Hubert H" uniqKey="Fernandez H" first="Hubert H" last="Fernandez">Hubert H. Fernandez</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, McKnight Brain Institute/University of Florida, Gainesville, Florida 32611, USA. fernandez@neurology.ufl.edu</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, McKnight Brain Institute/University of Florida, Gainesville, Florida 32611</wicri:regionArea><wicri:noRegion>Florida 32611</wicri:noRegion></affiliation></author><author><name sortKey="Aarsland, Dag" sort="Aarsland, Dag" uniqKey="Aarsland D" first="Dag" last="Aarsland">Dag Aarsland</name></author><author><name sortKey="Fenelon, Gilles" sort="Fenelon, Gilles" uniqKey="Fenelon G" first="Gilles" last="Fénelon">Gilles Fénelon</name></author><author><name sortKey="Friedman, Joseph H" sort="Friedman, Joseph H" uniqKey="Friedman J" first="Joseph H" last="Friedman">Joseph H. Friedman</name></author><author><name sortKey="Marsh, Laura" sort="Marsh, Laura" uniqKey="Marsh L" first="Laura" last="Marsh">Laura Marsh</name></author><author><name sortKey="Troster, Alexander I" sort="Troster, Alexander I" uniqKey="Troster A" first="Alexander I" last="Tröster">Alexander I. Tröster</name></author><author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name><affiliation><country>Autriche</country><placeName><settlement type="city">Innsbruck</settlement><region nuts="2" type="region">Tyrol (Land)</region></placeName><orgName type="university">Université de médecine d'Innsbruck</orgName></affiliation></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name></author><author><name sortKey="Sampaio, Cristina" sort="Sampaio, Cristina" uniqKey="Sampaio C" first="Cristina" last="Sampaio">Cristina Sampaio</name></author><author><name sortKey="Stebbins, Glenn T" sort="Stebbins, Glenn T" uniqKey="Stebbins G" first="Glenn T" last="Stebbins">Glenn T. Stebbins</name></author><author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G" last="Goetz">Christopher G. Goetz</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2008">2008</date><idno type="doi">10.1002/mds.21875</idno><idno type="RBID">pubmed:18175343</idno><idno type="pmid">18175343</idno><idno type="wicri:Area/PubMed/Corpus">002358</idno><idno type="wicri:Area/PubMed/Curation">002358</idno><idno type="wicri:Area/PubMed/Checkpoint">002090</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Scales to assess psychosis in Parkinson's disease: Critique and recommendations.</title><author><name sortKey="Fernandez, Hubert H" sort="Fernandez, Hubert H" uniqKey="Fernandez H" first="Hubert H" last="Fernandez">Hubert H. Fernandez</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, McKnight Brain Institute/University of Florida, Gainesville, Florida 32611, USA. fernandez@neurology.ufl.edu</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, McKnight Brain Institute/University of Florida, Gainesville, Florida 32611</wicri:regionArea><wicri:noRegion>Florida 32611</wicri:noRegion></affiliation></author><author><name sortKey="Aarsland, Dag" sort="Aarsland, Dag" uniqKey="Aarsland D" first="Dag" last="Aarsland">Dag Aarsland</name></author><author><name sortKey="Fenelon, Gilles" sort="Fenelon, Gilles" uniqKey="Fenelon G" first="Gilles" last="Fénelon">Gilles Fénelon</name></author><author><name sortKey="Friedman, Joseph H" sort="Friedman, Joseph H" uniqKey="Friedman J" first="Joseph H" last="Friedman">Joseph H. Friedman</name></author><author><name sortKey="Marsh, Laura" sort="Marsh, Laura" uniqKey="Marsh L" first="Laura" last="Marsh">Laura Marsh</name></author><author><name sortKey="Troster, Alexander I" sort="Troster, Alexander I" uniqKey="Troster A" first="Alexander I" last="Tröster">Alexander I. Tröster</name></author><author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name><affiliation><country>Autriche</country><placeName><settlement type="city">Innsbruck</settlement><region nuts="2" type="region">Tyrol (Land)</region></placeName><orgName type="university">Université de médecine d'Innsbruck</orgName></affiliation></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name></author><author><name sortKey="Sampaio, Cristina" sort="Sampaio, Cristina" uniqKey="Sampaio C" first="Cristina" last="Sampaio">Cristina Sampaio</name></author><author><name sortKey="Stebbins, Glenn T" sort="Stebbins, Glenn T" uniqKey="Stebbins G" first="Glenn T" last="Stebbins">Glenn T. Stebbins</name></author><author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G" last="Goetz">Christopher G. Goetz</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="eISSN">1531-8257</idno><imprint><date when="2008" type="published">2008</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Brief Psychiatric Rating Scale</term><term>Delusions (diagnosis)</term><term>Delusions (epidemiology)</term><term>Delusions (etiology)</term><term>Diagnostic and Statistical Manual of Mental Disorders</term><term>Hallucinations (diagnosis)</term><term>Hallucinations (epidemiology)</term><term>Hallucinations (etiology)</term><term>Health Planning Guidelines</term><term>Humans</term><term>Parkinson Disease (epidemiology)</term><term>Parkinson Disease (psychology)</term><term>Prevalence</term><term>Psychometrics</term><term>Psychotic Disorders (diagnosis)</term><term>Psychotic Disorders (epidemiology)</term><term>Psychotic Disorders (etiology)</term><term>Questionnaires</term><term>Severity of Illness Index</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Delusions</term><term>Hallucinations</term><term>Psychotic Disorders</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Delusions</term><term>Hallucinations</term><term>Parkinson Disease</term><term>Psychotic Disorders</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Delusions</term><term>Hallucinations</term><term>Psychotic Disorders</term></keywords><keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Brief Psychiatric Rating Scale</term><term>Diagnostic and Statistical Manual of Mental Disorders</term><term>Health Planning Guidelines</term><term>Humans</term><term>Prevalence</term><term>Psychometrics</term><term>Questionnaires</term><term>Severity of Illness Index</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Psychotic symptoms are a frequent occurrence in Parkinson's disease (PD), affecting up to 50% of patients. The Movement Disorder Society established a Task Force on Rating Scales in PD, and this critique applies to published, peer-reviewed rating psychosis scales used in PD psychosis studies. Twelve psychosis scales/questionnaires were reviewed. None of the reviewed scales adequately captured the entire phenomenology of PD psychosis. While the Task Force has labeled some scales as "recommended" or "suggested" based on the fulfilling-defined criteria, none of the current scales contained all the basic content, mechanistic and psychometric properties needed to capture PD psychotic phenomena and to measure clinical response over time. Different scales may be better for some settings versus others. Since one scale may not be able to serve all needs, a scale used to measure clinical response and change over time [such as the Clinical Global Impression Scale (CGIS)] may need to be combined with another scale better at cataloging specific features [such as the Neuropsychiatric Inventory (NPI) or Schedule for Assessment of Positive Symptoms (SAPS)]. At the present time, for clinical trials on PD psychosis assessing new treatments, the following are recommended primary outcome scales: NPI (for the cognitively impaired PD population or when a caregiver is required), SAPS, Positive and Negative Syndrome Scale (PANSS), or Brief Psychiatric Rating Scale (BPRS) (for the cognitively intact PD population or when the patient is the sole informant). The CGIS is suggested as a secondary outcome scale to measure change and response to treatment over time.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">18175343</PMID><DateCreated><Year>2008</Year><Month>04</Month><Day>03</Day></DateCreated><DateCompleted><Year>2008</Year><Month>07</Month><Day>22</Day></DateCompleted><DateRevised><Year>2010</Year><Month>02</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1531-8257</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>4</Issue><PubDate><Year>2008</Year><Month>Mar</Month><Day>15</Day></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Scales to assess psychosis in Parkinson's disease: Critique and recommendations.</ArticleTitle><Pagination><MedlinePgn>484-500</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/mds.21875</ELocationID><Abstract><AbstractText>Psychotic symptoms are a frequent occurrence in Parkinson's disease (PD), affecting up to 50% of patients. The Movement Disorder Society established a Task Force on Rating Scales in PD, and this critique applies to published, peer-reviewed rating psychosis scales used in PD psychosis studies. Twelve psychosis scales/questionnaires were reviewed. None of the reviewed scales adequately captured the entire phenomenology of PD psychosis. While the Task Force has labeled some scales as "recommended" or "suggested" based on the fulfilling-defined criteria, none of the current scales contained all the basic content, mechanistic and psychometric properties needed to capture PD psychotic phenomena and to measure clinical response over time. Different scales may be better for some settings versus others. Since one scale may not be able to serve all needs, a scale used to measure clinical response and change over time [such as the Clinical Global Impression Scale (CGIS)] may need to be combined with another scale better at cataloging specific features [such as the Neuropsychiatric Inventory (NPI) or Schedule for Assessment of Positive Symptoms (SAPS)]. At the present time, for clinical trials on PD psychosis assessing new treatments, the following are recommended primary outcome scales: NPI (for the cognitively impaired PD population or when a caregiver is required), SAPS, Positive and Negative Syndrome Scale (PANSS), or Brief Psychiatric Rating Scale (BPRS) (for the cognitively intact PD population or when the patient is the sole informant). The CGIS is suggested as a secondary outcome scale to measure change and response to treatment over time.</AbstractText><CopyrightInformation>(c) 2007 Movement Disorder Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fernandez</LastName><ForeName>Hubert H</ForeName><Initials>HH</Initials><AffiliationInfo><Affiliation>Department of Neurology, McKnight Brain Institute/University of Florida, Gainesville, Florida 32611, USA. fernandez@neurology.ufl.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aarsland</LastName><ForeName>Dag</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Fénelon</LastName><ForeName>Gilles</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Friedman</LastName><ForeName>Joseph H</ForeName><Initials>JH</Initials></Author><Author ValidYN="Y"><LastName>Marsh</LastName><ForeName>Laura</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Tröster</LastName><ForeName>Alexander I</ForeName><Initials>AI</Initials></Author><Author ValidYN="Y"><LastName>Poewe</LastName><ForeName>Werner</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Rascol</LastName><ForeName>Olivier</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Sampaio</LastName><ForeName>Cristina</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Stebbins</LastName><ForeName>Glenn T</ForeName><Initials>GT</Initials></Author><Author ValidYN="Y"><LastName>Goetz</LastName><ForeName>Christopher G</ForeName><Initials>CG</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D023361">Validation Studies</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Mov Disord. 2010 Jan 15;25(1):124-5</RefSource><PMID Version="1">19412941</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D010054">Brief Psychiatric Rating Scale</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003702">Delusions</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D039721">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006212">Hallucinations</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D006287">Health Planning Guidelines</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000523">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015995">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011594">Psychometrics</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011618">Psychotic Disorders</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D011795">Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012720">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>1</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>7</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>1</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="doi">10.1002/mds.21875</ArticleId><ArticleId IdType="pubmed">18175343</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Autriche</li><li>États-Unis</li></country><region><li>Tyrol (Land)</li></region><settlement><li>Innsbruck</li></settlement><orgName><li>Université de médecine d'Innsbruck</li></orgName></list><tree><noCountry><name sortKey="Aarsland, Dag" sort="Aarsland, Dag" uniqKey="Aarsland D" first="Dag" last="Aarsland">Dag Aarsland</name><name sortKey="Fenelon, Gilles" sort="Fenelon, Gilles" uniqKey="Fenelon G" first="Gilles" last="Fénelon">Gilles Fénelon</name><name sortKey="Friedman, Joseph H" sort="Friedman, Joseph H" uniqKey="Friedman J" first="Joseph H" last="Friedman">Joseph H. Friedman</name><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G" last="Goetz">Christopher G. Goetz</name><name sortKey="Marsh, Laura" sort="Marsh, Laura" uniqKey="Marsh L" first="Laura" last="Marsh">Laura Marsh</name><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><name sortKey="Sampaio, Cristina" sort="Sampaio, Cristina" uniqKey="Sampaio C" first="Cristina" last="Sampaio">Cristina Sampaio</name><name sortKey="Stebbins, Glenn T" sort="Stebbins, Glenn T" uniqKey="Stebbins G" first="Glenn T" last="Stebbins">Glenn T. Stebbins</name><name sortKey="Troster, Alexander I" sort="Troster, Alexander I" uniqKey="Troster A" first="Alexander I" last="Tröster">Alexander I. Tröster</name></noCountry><country name="États-Unis"><noRegion><name sortKey="Fernandez, Hubert H" sort="Fernandez, Hubert H" uniqKey="Fernandez H" first="Hubert H" last="Fernandez">Hubert H. Fernandez</name></noRegion></country><country name="Autriche"><region name="Tyrol (Land)"><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002090 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 002090 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:18175343
|texte= Scales to assess psychosis in Parkinson's disease: Critique and recommendations.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:18175343" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |